獣医学博士, 北海道大学

Life Science, Veterinary medical science

Doctoral (PhD) degree program, Graduate School of Veterinary Medicine

Jun. 2025, 日本獣医麻酔外科学会学術集会アワード
側方アプローチによる胸腔鏡下胸腺摘出術を実施した中型犬の1例
大脇 稜;細谷謙次;木村貴光;田村 純;賀川由美子;木之下怜平;金 尚昊;奥村正裕

Dec. 2024, 日本獣医麻酔外科学会学術集会アワード
膵部分切除により良好に血糖値が制御されたNesidioblastosis（膵島細胞症）の犬の1例
大脇 稜;細谷謙次;幸野瑠美;賀川由美子;竹内恭介;木之下怜平;金 尚昊;奥村正裕

Sep. 2024, 日本獣医学会学術集会優秀発表賞
イヌ腫瘍細胞株におけるJanus kinase阻害剤オクラシチニブの放射線増感作用の解析
大脇 稜;細谷謙次;金尚昊;須永隆文;奥村正裕

Jul. 2024, 日本獣医がん学会学術集会臨床部門アワード
積極的な外科切除により長期生存を認めた膵臓外分泌腺癌の犬の一例
大脇 稜;金 尚昊;木之下 怜平;竹内 恭介;細谷 謙次;奥村 正裕

Jun. 2017, 日本獣医麻酔外科学会学術集会アワード
肝臓尾状葉に発生した腫瘤病変に対し腹腔鏡下肝葉部分切除術を行った犬の1例
大脇 稜;渡部 あい;皆川 拓郎;鵜飼 綾子;門脇 巧;永本 哲朗;江原 郁也

Sep. 2015, 日本小動物獣医学会北海道地区学会奨励賞
胸骨切開下ベントラルスロット術にて治療した頚胸椎移行部における椎間板ヘルニアの犬の3例
大脇 稜;越後 良介;星 清貴;和泉 雄介;高木 哲;星野 有希;細谷 謙次;奥村 正裕

Effect of fuzapladib sodium hydrate on adhesion molecule expression in canine endothelial cells and neutrophils.
Kanittha Darawiroj; Takafumi Sunaga; Ryo Owaki; Nomsa Mulenga Handondo; Masahiro Okumura
The Journal of veterinary medical science, 31 Dec. 2025, [Domestic magazines]
English, Scientific journal, Neutrophil recruitment to inflamed tissue is mediated by adhesion molecules and chemokine signaling. Fuzapladib sodium hydrate (FZP) has been reported to reduce neutrophil infiltration, but its broader effect on adhesion molecules in dogs remains unclear. This study investigated the influence of FZP on canine aortic endothelial cells (CnAOEC) and primary neutrophils under cytokine stimulation. CnAOEC were treated with recombinant canine tumor necrosis factor alpha (rh-cTNFα) or lipopolysaccharide together with FZP, while neutrophils isolated from healthy dogs were preincubated with FZP before rh-cTNFα stimulation for gene and protein expression analyses. Expression of endothelial E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1) was quantified by qPCR. Neutrophil C-X-C motif chemokine receptor 2, P-selectin glycoprotein ligand-1 (PSGL-1), and L-selectin were also analyzed using qPCR. In addition, C-X-C motif chemokine ligand 1 and leukocyte function-associated antigen-1 (LFA-1) were determined using ELISA and flow cytometry, respectively. Neutrophil adhesion to FZP-treated endothelial monolayers was evaluated under static conditions. FZP significantly downregulated endothelial P-selectin at the highest dose, whereas ICAM-1 was upregulated. In neutrophils, FZP decreased L-selectin and PSGL-1 expression at the highest concentration. These findings suggest that FZP selectively modulates early adhesion through suppression of P-selectin, L-selectin, and PSGL-1, which may weaken rolling and tethering interactions between cells. Although functional adhesion effects were limited, these molecular responses provide further insight into the anti-inflammatory effect of FZP.

Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.
Satoshi Takagi; Michihito Tagawa; Naoya Maekawa; Satoru Konnai; Yumiko Kagawa; Kenji Hosoya; Akinori Yamauchi; Ayano Kudo; Shintaro Kamo; Sangho Kim; Ryohei Kinoshita; Tatsuya Deguchi; Ryo Owaki; Yurika Tachibana; Madoka Yokokawa; Hiroto Takeuchi; Hayato Nakamura; Yukinari Kato; Shigeki Kanazawa; Tomoyuki Abe; Takuya Furuta; Keiichi Yamamoto; Yasuhiko Suzuki; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
The Journal of veterinary medical science, 87, 12, 1419, 1425, 01 Dec. 2025, [Domestic magazines]
English, Scientific journal, Cancer in dogs remains a major challenge in modern veterinary medicine. Immunotherapy using immune checkpoint inhibitors (ICIs) is available for various human tumor types, and recent veterinary clinical studies have shown that ICIs are a promising approach for treating canine cancers. A canine chimeric anti-PD-L1 antibody, c4G12 (HFC-L1), has been investigated for canine cancer immunotherapy; however, its clinical benefits have not been well characterized in tumors other than pulmonary metastatic (stage IV) oral malignant melanoma (OMM). To explore the efficacy and safety of HFC-L1, we conducted a clinical study in dogs with stage I-III OMM or other tumor types (n=12). HFC-L1 treatment at a dose of 5 mg/kg every 2 weeks was well tolerated, and no grade 3 or higher treatment-related adverse events were reported. Among the dogs eligible for response evaluation (n=10), a partial response was observed in one dog with squamous cell carcinoma, resulting in an objective response rate of 10%. In addition, in a dog with ceruminous cell carcinoma, clinical evidence of a tumor response was observed in metastatic lung lesions. Together, these results suggest that the HFC-L1 therapy is applicable for the treatment of various tumor types, although its clinical benefits should be further evaluated in clinical studies involving a larger number of dogs with each tumor type.

Successful surgical removal of a retroperitoneal paraganglioma in the celiac artery trifurcation in a dog.
Kyosuke Takeuchi; Kenji Hosoya; Ryo Owaki; Ryohei Kinoshita; Sangho Kim; Masahiro Okumura
BMC veterinary research, 21, 1, 651, 651, 07 Nov. 2025, [International Magazine]
English, Scientific journal, BACKGROUND: Paraganglioma (PGL) is a general term for tumors that originate in the paraganglia in dogs, most commonly reported in the carotid and aortic bodies. Reports on surgical treatment are rare because these tumors develop near large blood vessels, and their prognosis remains unclear. In dogs, the indications for and safety of surgical procedures involving the celiac artery (CA) root and the dissection of its major branches have not been established. To the best of our knowledge, this is the first reported case of CA root involvement in canine PGL. CASE PRESENTATION: Surgery was performed on day 84 to remove a PGL tumor. The mass was firmly attached to the left lobe of the pancreas, portal vein, CA, and cranial mesenteric artery (CMA). Therefore, a combined resection was performed, including the spleen, left lobe of the pancreas, and left hepatic lymph nodes. Among the main branches of the CA, the splenic and left gastric arteries could not be separated and were transected. Consequently, the stomach wall became ischemic, and reduced pulsation of the left gastric and omental arteries was observed. To maintain blood supply, the common hepatic artery was preserved. After normalization of the stomach wall color, the CMA was separated from the mass, and the tumor was removed. Pathological examination confirmed that the mass was a PGL, with no metastasis to the hepatic lymph nodes. A computed tomography scan on day 265 revealed that blood flow in the common hepatic artery, portal vein, and left gastric region was well maintained. As of day 279, there was no evidence of metastasis or recurrence, and the patient remained in good condition. CONCLUSIONS: In this case, the main branches of the CA, except for the common hepatic artery, were transected to remove the mass; however, the patient was discharged without serious complications. This is attributable to recovery of blood flow from collateral routes. Considering this blood flow recovery and that intraoperative gastric ischemia was temporary, complete ligation of the CA root may be acceptable in some cases. Additionally, the prognosis for PGL was favorable when complete resection was achieved.

Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Kenji Hosoya; Sangho Kim; Ryohei Kinoshita; Naoya Maekawa; Satoru Konnai; Satoshi Takagi; Michihito Tagawa; Yumiko Kagawa; Tatsuya Deguchi; Ryo Owaki; Yurika Tachibana; Madoka Yokokawa; Hiroto Takeuchi; Hayato Nakamura; Akinori Yamauchi; Ayano Kudo; Shintaro Kamo; Yukinari Kato; Shigeki Kanazawa; Tomoyuki Abe; Takuya Furuta; Keiichi Yamamoto; Yasuhiko Suzuki; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
Veterinary sciences, 12, 9, 02 Sep. 2025, [International Magazine]
English, Scientific journal, Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose-response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8-9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5-10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.

Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs
Naoya Maekawa; Satoru Konnai; Kei Watari; Hiroto Takeuchi; Takeshi Nakanishi; Taro Tachibana; Kenji Hosoya; Sangho Kim; Ryohei Kinoshita; Ryo Owaki; Madoka Yokokawa; Yumiko Kagawa; Satoshi Takagi; Tatsuya Deguchi; Hiroshi Ohta; Yukinari Kato; Satoshi Yamamoto; Keiichi Yamamoto; Yasuhiko Suzuki; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
Frontiers in Immunology, 16, Frontiers Media SA, 20 May 2025
Scientific journal, Immune checkpoint inhibitors (ICIs) are widely used for cancer immunotherapy; however, the clinical efficacy of anti-PD-1/PD-L1 monotherapy is generally limited, highlighting the need to develop combination therapies. Dogs develop spontaneous tumors in immunocompetent settings, and anti-PD-1/PD-L1 antibodies exert similar clinical benefits. However, no clinically relevant anti-CTLA-4 antibody has been reported, limiting the value of canine tumors as comparative models for human ICI research. Here, canine CTLA-4 was molecularly characterized, and a caninized anti-CTLA-4 antibody (ca1C5) that blocks CTLA-4/ligand binding was developed. Treatment with ca1C5 increased cytokine production in canine immune cell cultures, and the immunostimulatory effect was enhanced when used in combination with the anti-PD-L1 antibody c4G12. As a proof-of-concept, a veterinary clinical study was conducted to demonstrate the safety and clinical efficacy of anti-CTLA-4 antibody as salvage combination therapy in dogs with advanced tumors refractory to prior c4G12 monotherapy. The combination treatment (c4G12 plus ca1C5) was well-tolerated, and evidence of antitumor activity was observed in one dog with oral malignant melanoma. Further studies are warranted to advance veterinary care for dogs and to better characterize canine ICI models for human onco-immunology research.

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.
Ryo Owaki; Kenji Hosoya; Tatsuya Deguchi; Satoru Konnai; Naoya Maekawa; Tomohiro Okagawa; Hironobu Yasui; Sangho Kim; Takafumi Sunaga; Masahiro Okumura
Molecular therapy. Oncology, 33, 1, 200946, 200946, 20 Mar. 2025, [International Magazine]
English, Scientific journal, A combination of irradiation and oclacitinib, a Janus kinase (JAK) inhibitor used in dogs, could lead to synergistic anticancer effects in canine tumors. However, the anti-tumor effects of oclacitinib remain unclear. This study investigated the radio-sensitizing effect of oclacitinib in canine tumors and determined its underlying mechanisms using osteosarcoma (HMPOS), malignant melanoma (CMeC), and thyroid adenocarcinoma (CTAC) cell lines. A clonogenic assay and a tumor growth assessment in a xenograft mouse model (BALB/cAJcl-nu/nu) were performed to evaluate the radio-sensitizing effects of oclacitinib. Oclacitinib enhanced the radio-sensitivity of tumor cells both in vitro and in vivo. The signal transducer and activator of transcription (STAT)3 expression was activated and suppressed by oclacitinib in X-irradiation-exposed cells. Oclacitinib enhanced radiation-induced apoptosis only in HMPOS cells by inhibiting anti-apoptotic genes. In addition, oclacitinib inhibited the transcription of cell-cycle-regulating genes and arrested cell cycle progression from the G1 phase to subsequent phases. In conclusion, oclacitinib enhanced radio-sensitivity both in vitro and in vivo by triggering apoptosis and impeding cell cycle progression via STAT3 inhibition in canine tumor cell lines. This study suggested the clinical therapeutic potential of oclacitinib and radiation therapy in enhancing treatment efficacy and outcomes in canine tumors.

Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.
Ryo Owaki; Tatsuya Deguchi; Satoru Konnai; Naoya Maekawa; Tomohiro Okagawa; Kenji Hosoya; Sangho Kim; Takafumi Sunaga; Masahiro Okumura
Veterinary and comparative oncology, 21, 2, 279, 290, Jun. 2023, [Peer-reviewed], [Lead author], [International Magazine]
English, Scientific journal, Expression of programmed death ligand 1 (PD-L1) on tumour cells provides an immune evasion mechanism by inducing suppression of cytotoxic T cells. Various regulatory mechanisms of PD-L1 expression have been described in human tumours, however, little is known in canine tumours. To investigate whether inflammatory signalling is involved in PD-L1 regulation in canine tumours, the effects of interferon (IFN)-γ and tumour necrosis factor (TNF)-α treatment were examined in canine malignant melanoma cell lines (CMeC and LMeC) and an osteosarcoma cell line (HMPOS). The protein level of PD-L1 expression was upregulated by IFN-γ and TNF-α stimulation. Upon IFN-γ stimulation, all cell lines showed an increase in expression of PD-L1, signal transducer and activator of transcription (STAT)1, STAT3 and genes regulated by STAT activation. Upregulated expression of these genes was suppressed by the addition of a JAK inhibitor, oclacitinib. Contrastingly, upon TNF-α stimulation, all cell lines exhibited higher gene expression of the nuclear factor kappa B (NF-κB) gene RELA and genes regulated by NF-κB activation, whereas expression of PD-L1 was upregulated in LMeC only. Upregulated expression of these genes was suppressed by the addition of an NF-κB inhibitor, BAY 11-7082. The expression level of cell surface PD-L1 induced by IFN-γ and TNF-α treatment was reduced by oclacitinib and BAY 11-7082, respectively, indicating that upregulation of PD-L1 expression by IFN-γ and TNF-α stimulation is regulated via the JAK-STAT and NF-κB signalling pathways, respectively. These results provide insights into the role of inflammatory signalling in PD-L1 regulation in canine tumours.

Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma.
Tatsuya Deguchi; Naoya Maekawa; Satoru Konnai; Ryo Owaki; Kenji Hosoya; Keitaro Morishita; Motoji Nakamura; Tomohiro Okagawa; Hiroto Takeuchi; Sangho Kim; Ryohei Kinoshita; Yurika Tachibana; Madoka Yokokawa; Satoshi Takagi; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Cancers, 15, 11, 01 Jun. 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, Although immune checkpoint inhibitors (ICIs), such as the anti-programmed death-ligand 1 (PD-L1) antibody, have been developed for the treatment of canine malignant melanoma, desirable clinical efficacies have not been achieved. Recent studies in humans have suggested that radiation therapy (RT) combined with ICIs induces robust systemic antitumour immunity in patients with cancer. This study retrospectively examined the therapeutic efficacy of combination therapy (hypofractionated RT and anti-PD-L1 antibody [c4G12]) in dogs with pulmonary metastatic oral malignant melanoma. The intrathoracic clinical benefit rate (CBR)/median overall survival (OS) in the no RT (n = 20, free from the effect of RT), previous RT (n = 9, received RT ≤8 weeks prior to the first c4G12 dose), and concurrent RT (n = 10, c4G12 therapy within ±1 week of the first RT fraction) groups were 10%/185 days, 55.6%/283.5 days (p < 0.05 vs. no RT group), and 20%/129 days (p > 0.05 vs. no RT group), respectively. The adverse events were considered to be tolerable in the combination therapy. Thus, hypofractionated RT before the initiation of c4G12 therapy can be an effective approach for enhancing the therapeutic efficacy of immunotherapy, with acceptable safety profiles. Further prospective clinical studies are required to confirm the findings of this study.

Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Naoya Maekawa; Satoru Konnai; Kenji Hosoya; Sangho Kim; Ryohei Kinoshita; Tatsuya Deguchi; Ryo Owaki; Yurika Tachibana; Madoka Yokokawa; Hiroto Takeuchi; Yumiko Kagawa; Satoshi Takagi; Hiroshi Ohta; Yukinari Kato; Satoshi Yamamoto; Keiichi Yamamoto; Yasuhiko Suzuki; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
PloS one, 18, 10, e0291727, 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, Immune checkpoint inhibitors (ICIs) have been developed for canine tumour treatment, and pilot clinical studies have demonstrated their antitumour efficacy in dogs with oral malignant melanoma (OMM). Although ICIs have been approved for various human malignancies, their clinical benefits in other tumour types remain to be elucidated in dogs. Here, we conducted a clinical study of c4G12, a canine chimeric anti-PD-L1 antibody, to assess its safety and efficacy in dogs with various advanced malignant tumours (n = 12) at the Veterinary Teaching Hospital of Hokkaido University from 2018 to 2023. Dogs with digit or foot pad malignant melanoma (n = 4), osteosarcoma (n = 2), hemangiosarcoma (n = 1), transitional cell carcinoma (n = 1), nasal adenocarcinoma (n = 1), B-cell lymphoma (n = 1), or undifferentiated sarcoma (n = 2) were treated with 2 or 5 mg/kg c4G12 every 2 weeks. Treatment-related adverse events of any grade were observed in eight dogs (66.7%), including elevated aspartate aminotransferase (grade 3) in one dog (8.3%) and thrombocytopenia (grade 4) in another dog (8.3%). Among dogs with target disease at baseline (n = 8), as defined by the response evaluation criteria for solid tumours in dogs (cRECIST), one dog with nasal adenocarcinoma and another with osteosarcoma experienced a partial response (PR), with an objective response rate of 25.0% (2 PR out of 8 dogs; 95% confidence interval: 3.2-65.1%). These results suggest that c4G12 is safe and tolerable and shows antitumor effects in dogs with malignant tumours other than OMM. Further clinical studies are warranted to identify the tumour types that are most likely to benefit from c4G12 treatment.

Unrecognized difficult airway management during anesthesia in two brachycephalic dogs with narrow cricoid cartilage.
Jun Tamura; Norihiko Oyama; So Matsumoto; Ryo Owaki; Kenji Hosoya; Masahiro Okumura
The Journal of veterinary medical science, 83, 2, 234, 240, 25 Feb. 2021, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, Difficulty in airway management during anesthesia was noted in a 10-year-old, castrated, male Pekingese dog and a 13-year-old male French Bulldog. They showed strong resistance during tracheal tube insertion through the subglottic lumen. Therefore, the airway was secured by using a small endotracheal tube or supraglottic airway device. Computed tomography scan revealed a markedly narrower vertical dimension of the cricoid cartilage compared to that seen in common brachycephalic breeds. Posterior glottis was relatively more accessible for translaryngeal intubation in the present cases. Our findings showed that brachycephalic airway syndrome may be associated with narrow cricoid cartilage. To the best of our knowledge, this is the first clinical case report of airway management during anesthesia in dogs with narrow cricoid cartilage.

Thoracoscopic hilar lung lobectomy in two dogs.
Ikuya Ehara; Ryo Owaki; Ko Kadowaki; Kazushi Asano
Veterinary Record Case Reports, 8, 4, Dec. 2020, [Peer-reviewed]

胸腔鏡下結紮術を適用した先天性体肺動脈瘻の犬の1例
細谷謙次; 細谷謙次; 丸子冬聖; 大山紀彦; 大脇稜; 川元誠; 木之下怜平; 金尚昊; 金尚昊; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(CD-ROM), 110th, 2025

犬腫瘍細胞におけるInterferon-γおよびTumor necrosis factor-αによるProgrammed death ligand1発現経路の解析
大脇稜, 北海道獣医師会雑誌, 68, 7, 2024

免疫チェックポイント分子Programmed death-ligand1(PD-L1)を標的とした抗体薬による犬の鼻腔内腺癌に対する免疫療法の検討
多田佳史; 前川直也; 今内覚; 細谷謙次; 大脇稜; 竹内寛人; 賀川由美子; 高木哲; 高木哲; 鈴木定彦; 鈴木定彦; 岡川朋弘; 村田史郎; 大橋和彦, 日本獣医学会学術集会講演要旨集, 166th, 2023

胸管の単離遮断により治療した特発性乳び胸の犬の2例
細谷謙次; 細谷謙次; 大脇稜; 竹内恭介; 木之下怜平; 金尚昊; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(Web), 103rd, 2022

回盲部切除を実施した犬および猫14例の長期的合併症に関する回顧的研究
大脇稜; 細谷謙次; 細谷謙次; 竹内恭介; 木之下怜平; 金尚昊; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(Web), 105th, 2022

門脈静脈連結部での選択的結紮に術中超音波ガイドが有用であった右肝区域肝内門脈体循環短絡症の犬の1例
松本創; 細谷謙次; 細谷謙次; 大脇稜; 大山紀彦; 竹内恭介; 木之下怜平; 金尚昊; 滝口満喜; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(Web), 105th, 2022

肝尾状葉尾状突起に発生した腫瘤性病変に対して腹腔鏡下肝切除術を実施した犬の1例
星清貴; 大脇稜; 伊丹貴晴; 新田浩幸; 江原郁也, 日本獣医麻酔外科学会学術集会抄録集(Web), 105th, 2022

犬の口腔内悪性黒色腫に対する抗Programmed death-Ligand 1抗体療法と放射線治療におけるアブスコパル効果の誘導解析
大脇稜; 出口辰弥; 細谷謙次; 今内覚; 前川直也; 立花由莉加; 中村基司; 金尚昊; 須永隆文; 奥村正裕, 北海道獣医師会雑誌, 65, 8, 2021

三次元CADモデルが内視鏡外科の手術支援に有用であった犬の2例
細谷謙次; 大脇稜; 松本創; 木之下怜平; 金尚昊; 奥村正裕, 北海道獣医師会雑誌, 65, 8, 2021

イヌ腫瘍細胞株におけるProgrammed cell death-ligand1の発現機序の解析
大脇稜; 出口辰弥; 今内覚; 前川直也; 細谷謙次; 金尚昊; 須永隆文; 奥村正裕, 日本獣医学会学術集会講演要旨集, 164th (CD-ROM), 2021

胸腔内異所性肝組織からの出血を認めた犬の1例
金尚昊; 大脇稜; 賀川由美子; 細谷謙次; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(Web), 102nd, 2021

犬の気胸に対する胸腔鏡下肺葉切除術の治療成績
江原郁也; 江原郁也; 大脇稜; 皆川拓郎; 門脇功; 門脇功; 河村幸浩; 鈴木一平; 加藤大; 高木彩夏; 松本達哉; 進藤まこと; 進藤まこと; 浅野和之, 日本獣医麻酔外科学雑誌(Web), 50, Supplement 1, 2019

内視鏡外科~胸腔鏡・腹腔鏡の利点を活かした外科手術~腹腔鏡補助下膀胱結石摘出術
大脇稜; 江原郁也, Surgeon, 22, 4, 2018

右肺中葉に発生した肺嚢胞に対し,体内結紮による胸腔鏡下肺葉切除術を実施した犬の1例
大脇稜; 渡部あい; 皆川拓郎; 門脇巧; 河村幸浩; 加藤大; 高木彩夏; 鈴木一平; 松本達哉; 進藤充; 進藤充; 江原郁也; 江原郁也, 日本獣医麻酔外科学雑誌, 49, Supplement 1, 2018

胸腔鏡下にて胸腺腫を摘出した犬の1例
大脇稜; 渡部あい; 皆川拓郎; 門脇巧; 永本哲朗; 江原郁也; 江原郁也, 日本獣医麻酔外科学雑誌, 48, Supplement 2, 2017

肝尾状葉乳頭突起に発生した腫瘤病変に対し,腹腔鏡下肝葉部分切除術を行った犬の1例
大脇稜; 渡部あい; 皆川拓郎; 鵜飼綾子; 門脇巧; 永本哲朗; 江原郁也; 江原郁也, 日本獣医麻酔外科学雑誌, 48, Supplement 1, 2017

胸骨切開下ベントラルスロット術にて治療した頸胸椎移行部における椎間板ヘルニアの犬の3例
大脇稜; 越後良介; 星清貴; 和泉雄介; 高木哲; 星野有希; 細谷謙次; 奥村正裕, 北海道獣医師会雑誌, 59, 8, 2015

膵部分切除により良好に血糖値が制御されたNesidioblastosis（膵島細胞症）の犬の1例
大脇 稜; 細谷謙次; 幸野瑠美; 賀川由美子; 竹内恭介; 木之下怜平; 金 尚昊; 奥村正裕
第109回日本獣医麻酔外科学会学術集会, 22 Dec. 2024, Japanese, Oral presentation
20 Dec. 2024 - 22 Dec. 2024

イヌ腫瘍細胞株におけるJanus kinase阻害剤オクラシチニブの放射線増感作用の解析
大脇 稜; 谷謙次; 金; 尚昊; 須永隆文; 奥村正裕
第167回日本獣医学会学術集会, 12 Sep. 2024, Japanese, Oral presentation
10 Sep. 2024 - 13 Sep. 2024

積極的な外科切除により長期生存を認めた膵臓外分泌腺癌の犬の一例
大脇 稜; 金 尚昊; 木之下怜平; 竹内恭介; 細谷謙次; 奥村正裕
第30回獣医がん学会, 06 Jul. 2024, Japanese, Oral presentation
06 Jul. 2024 - 07 Jul. 2024

Enhancement of radiotherapy by oclacitinib-mediated inhibition of JAK signaling in a canine osteosarcoma cell line
Owaki R; Deguchi T; Konnai S; Maekawa N; Hosoya K; Kim S; Sunaga T; Okumura M
World Veterinary Cancer Conference 2024, Mar. 2024

回盲部切除を実施した犬および猫14例の長期的合併症に関する回顧的研究
大脇 稜; 細谷 謙次; 竹内 恭介; 木之下 怜平; 金 尚昊; 奥村 正裕
第105回日本獣医麻酔外科学会学術集会, 24 Dec. 2022

Regulation of programmed death ligand 1 expression by interferon-γ and tumor necrosis factor-α in canine tumor cell lines
Owaki R; Deguchi T; Konnai S; Maekawa N; Hosoya K; Kim S; Sunaga T; Okumura M
The 10th Sapporo Summer Seminar for One Health (SaSSOH), Sep. 2022

Analysis for the mechanism of programmed death ligand 1 expression on canine tumor cell lines
Owaki R; Deguchi T; Konnai S; Maekawa N; Hosoya K; Kim S; Sunaga T; Okumura M
The 9th Sapporo Summer Seminar for One Health (SaSSOH), Sep. 2021

犬の口腔内悪性黒色腫に対する抗Programmed death-ligand 1抗体療法と放射線治療におけるアブスコパル効果の誘導解析
大脇 稜; 出口 辰弥; 細谷 謙次; 今内 覚; 前川 直也; 立花 由莉加; 中村 基司; 金 尚昊; 須永 隆文; 奥村 正裕
令和3年度北海道地区学会, Sep. 2021

イヌ腫瘍細胞株におけるProgrammed death-ligand 1の発現機序の解析
大脇 稜; 出口 辰弥; 今内 覚; 前川 直也; 細谷 謙次; 金 尚昊; 須永 隆文; 奥村 正裕
第164回日本獣医学会学術集会, Sep. 2021

右肺中葉に発生した肺気腫に対し体内結紮による胸腔鏡下肺葉切除術を実施した犬の1例
大脇 稜; 渡部 あい; 皆川 拓郎; 門脇 巧; 河村 幸浩; 加藤 大; 高木 彩夏; 鈴木 一平; 松本 達哉; 進藤 充; 江原 郁也
第96回獣医麻酔外科学会学術集会, 16 Jun. 2018

胸腔鏡下にて胸腺腫を摘出した犬の1例
大脇 稜; 渡部 あい; 皆川 拓郎; 門脇 巧; 永本 哲朗; 江原 郁也
第95回獣医麻酔外科学会学術集会, 09 Dec. 2017

肝臓尾状葉に発生した腫瘤病変に対し腹腔鏡下肝葉部分切除術を行った犬の1例
大脇 稜; 渡部 あい; 皆川 拓郎; 鵜飼 綾子; 門脇 巧; 永本 哲朗; 江原 郁也
第94回獣医麻酔外科学会学術集会, 17 Jun. 2017

胸骨切開下ベントラルスロット術にて治療した頚胸椎移行部における椎間板ヘルニアの犬の3例
大脇 稜; 越後 良介; 星 清貴; 和泉 雄介; 高木 哲; 星野 有希; 細谷 謙次; 奥村 正裕
平成27年度北海道地区学会, 16 Sep. 2015

プレクリニカル実習, 2024年, 学士課程, 獣医学部

プレクリニカル実習, 2024年, 学士課程, 獣医学部

イヌ腫瘍に対するJAK阻害薬オクラシチニブの放射線増感薬への応用に向けた臨床研究
科学研究費助成事業
01 Apr. 2025 - 31 Mar. 2027
大脇 稜
日本学術振興会, 若手研究, 北海道大学, 25K18354